S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
Log in
NYSEAMERICAN:ARMP

Armata Pharmaceuticals Stock Forecast, Price & News

$5.59
-0.16 (-2.78 %)
(As of 02/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.55
Now: $5.59
$5.79
50-Day Range
$2.65
MA: $2.87
$3.12
52-Week Range
$2.52
Now: $5.59
$10.48
Volume27,325 shs
Average Volume66,774 shs
Market Capitalization$104.54 million
P/E RatioN/A
Dividend YieldN/A
Beta1.74
Armata Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for the treatment of antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates includes AP-SA02, which is in Phase 1b/2 clinical trial and AP-SA01 that targets staphylococcus aureus, including multidrug-resistant strains. It is also developing and advancing AP-PA02 that is in Phase 1b/2 clinical trial for treating diseases caused by pseudomonas aeruginosa. The company is headquartered in Marina del Rey, California.
Armata Pharmaceuticals logo

Headlines

See More Headlines

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:ARMP
CUSIPN/A
CIKN/A
Phone(310) 655-2928
Employees33
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.47 per share

Profitability

Net Income$-19,480,000.00

Miscellaneous

Market Cap$104.54 million
Next Earnings Date3/18/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.66 out of 5 stars

Medical Sector

288th out of 1,962 stocks

Biological Products, Except Diagnostic Industry

33rd out of 177 stocks

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$5.59
-0.16 (-2.78 %)
(As of 02/26/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ARMP News and Ratings via Email

Sign-up to receive the latest news and ratings for ARMP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Frequently Asked Questions

Is Armata Pharmaceuticals a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Armata Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Armata Pharmaceuticals stock.
View analyst ratings for Armata Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Armata Pharmaceuticals?

Wall Street analysts have given Armata Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Armata Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Armata Pharmaceuticals?

Armata Pharmaceuticals saw a decline in short interest in February. As of February 12th, there was short interest totaling 55,700 shares, a decline of 44.1% from the January 28th total of 99,600 shares. Based on an average trading volume of 51,400 shares, the short-interest ratio is currently 1.1 days.
View Armata Pharmaceuticals' Short Interest
.

When is Armata Pharmaceuticals' next earnings date?

Armata Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, March 18th 2021.
View our earnings forecast for Armata Pharmaceuticals
.

How were Armata Pharmaceuticals' earnings last quarter?

Armata Pharmaceuticals Inc. (NYSEAMERICAN:ARMP) issued its quarterly earnings results on Thursday, November, 12th. The company reported ($0.31) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.20) by $0.11. The company had revenue of $0.29 million for the quarter, compared to analyst estimates of $1.75 million.
View Armata Pharmaceuticals' earnings history
.

What price target have analysts set for ARMP?

4 Wall Street analysts have issued 1 year price objectives for Armata Pharmaceuticals' stock. Their forecasts range from $5.00 to $9.00. On average, they expect Armata Pharmaceuticals' share price to reach $7.33 in the next twelve months. This suggests a possible upside of 31.2% from the stock's current price.
View analysts' price targets for Armata Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Armata Pharmaceuticals' key executives?

Armata Pharmaceuticals' management team includes the following people:
  • Mr. Todd R. Patrick, CEO & Director (Age 58, Pay $556.2k)
  • Dr. Brian Varnum, Pres & Chief Devel. Officer (Age 61, Pay $409.6k)
  • Mr. Steven R. Martin, Sr. VP & CFO (Age 60, Pay $409.6k)
  • Dr. Wenyuan Shi, Co-Founder & Founding Scientist
  • Mr. Duane Alfred Morris B.A., BA, VP of Operations (Age 71)

Who are some of Armata Pharmaceuticals' key competitors?

What other stocks do shareholders of Armata Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Armata Pharmaceuticals investors own include VBI Vaccines (VBIV), Vaxart (VXRT), Amarin (AMRN), (ALT), CRISPR Therapeutics (CRSP), Pfizer (PFE), Micron Technology (MU), Aduro Biotech (ADRO), Occidental Petroleum (OXY) and Gilead Sciences (GILD).

What is Armata Pharmaceuticals' stock symbol?

Armata Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ARMP."

Who are Armata Pharmaceuticals' major shareholders?

Armata Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (0.53%) and BlackRock Inc. (0.19%).
View institutional ownership trends for Armata Pharmaceuticals
.

Which institutional investors are selling Armata Pharmaceuticals stock?

ARMP stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc..
View insider buying and selling activity for Armata Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Armata Pharmaceuticals stock?

ARMP stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.
View insider buying and selling activity for Armata Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Armata Pharmaceuticals?

Shares of ARMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Armata Pharmaceuticals' stock price today?

One share of ARMP stock can currently be purchased for approximately $5.59.

How much money does Armata Pharmaceuticals make?

Armata Pharmaceuticals has a market capitalization of $104.54 million. The company earns $-19,480,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis.

How many employees does Armata Pharmaceuticals have?

Armata Pharmaceuticals employs 33 workers across the globe.

What is Armata Pharmaceuticals' official website?

The official website for Armata Pharmaceuticals is www.armatapharma.com.

Where are Armata Pharmaceuticals' headquarters?

Armata Pharmaceuticals is headquartered at 4503 GLENCOE AVENUE, MARINA DEL REY CA, 90292.

How can I contact Armata Pharmaceuticals?

Armata Pharmaceuticals' mailing address is 4503 GLENCOE AVENUE, MARINA DEL REY CA, 90292. The company can be reached via phone at (310) 655-2928 or via email at [email protected]


This page was last updated on 2/28/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.